Test Code PLINK Paroxysmal Nocturnal Hemoglobinuria, PI-Linked Antigen, Blood
Additional Codes
Sunquest: PLINKM
EPIC: LAB13113
Reporting Name
PNH, PI-Linked AG, BUseful For
Screening for and confirming the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)
Monitoring patients with PNH
Additional Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
FCIMS | Flow Cytometry Interp, 9-15 Markers | No, (Bill Only) | Yes |
Method Name
Immunophenotyping
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Whole bloodSpecimen Required
Specimen must arrive within 3 days of collection.
Container/Tube:
Preferred: Yellow top (ACD solution A or B)
Acceptable: Lavender top (EDTA)
Specimen Volume: 2.6 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole blood | Ambient (preferred) | 72 hours | |
Refrigerated | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Fully Clotted | Reject |
Reference Values
An interpretive report will be provided.
RED BLOOD CELLS:
PNH RBC-Partial Antigen loss: 0.00-0.99%
PNH RBC-Complete Antigen loss: 0.00-0.01%
PNH Granulocytes: 0.00-0.01%
PNH Monocytes: 0.00-0.05%
Day(s) Performed
Monday through Saturday
CPT Code Information
88184-Flow cytometry, RBC x 1
88184-Flow cytometry, WBC x 1
88185-Flow cytometry, additional marker (each), RBC x 1
88185-Flow cytometry, additional marker (each), WBC x 6
88188-Flow Cytometry Interpretation, 9-15 Markers x 1
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PLINK | PNH, PI-Linked AG, B | 90735-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
CK079 | Interpretation | 90739-4 |
CK080 | PNH RBC-Partial Ag Loss | 33662-8 |
CK081 | PNH RBC-Complete Ag Loss | 90738-6 |
CK082 | PNH Granulocytes | 90737-8 |
CK083 | PNH Monocytes | 90736-0 |
Clinical Information
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematologic disorder characterized by nocturnal hemoglobinuria, chronic hemolytic anemia, thrombosis, pancytopenia, and, in some patients, acute or chronic myeloid malignancies.
Paroxysmal nocturnal hemoglobinuria appears to be a hematopoietic stem cell disorder that affects erythroid, granulocytic, and megakaryocytic cell lines. The abnormal cells in PNH have been shown to lack glycosylphosphatidylinositol (GPI)-linked proteins in erythroid, granulocytic, megakaryocytic, and, in some instances, lymphoid cells. Variants in the phosphatidylinositol glycan A gene, PIGA, have been identified consistently in patients with PNH, thus confirming the biological defect in this disorder.
A flow cytometric-based assay can detect the presence or absence of these GPI-linked proteins in granulocytes, monocytes, erythrocytes, and lymphocytes, thus avoiding the problems associated with red blood cell (RBC)-based diagnostic methods (Ham test) in which recent hemolytic episodes or recent transfusions can give false-negative results. A partial list of known GPI-linked proteins includes CD14, CD16, CD24, CD55, CD56, CD58, CD59, C8-binding protein, alkaline phosphatase, acetylcholine esterase, and a variety of high frequency human blood antigens. In addition, fluorescent aerolysin binds directly to the GPI anchor and can be used to evaluate the expression of the GPI linkage.
In-house studies, as well as others in the literature, have shown that flow cytometry-based assays will detect all Ham-positive PNH cases, as well as some Ham-negative PNH cases. This assay replaces the sugar water test and the Ham test for the evaluation of patients with possible PNH.
Patients with PNH should be transfused with ABO-specific reb blood cells (RBCs), which do not need to be washed. If, for some reason, they need to receive non-ABO type-specific (type O) cells, these RBC units should be washed. Since recipient antibodies to granulocyte antigens can trigger hemolytic episodes in PNH, if they have such antibodies these patients should receive leukoreduced RBCs and platelets.
Specimen Retention Time
14 daysTest Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.Report Available
1 to 3 daysForms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen: